Navigation Links
Nucletron Spotlights Innovations During ESTRO29
Date:9/10/2010

Nucletron Spotlights Innovations During ESTRO29 -- VEENENDAAL, The Netherlands, September 10, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, New Products & Services, Trade Show News Click to view news release full screen  

Nucletron Spotlights Innovations During ESTRO29

 

VEENENDAAL, The Netherlands, September 10, 2010 /PRNewswire/ --

- Exciting New Solutions for Precision Cancer Treatment on Display During ESTRO29 in Barcelona, Spain

Nucletron, a leading provider of state of the art radiotherapy solutions for cancer treatment, today announced a large number of exciting innovations for precise cancer treatment that will be in the spotlight during ESTRO29 in Barcelona. The company will be showcasing the latest developments in cancer treatment solutions for both brachytherapy and external beam.

The complete program for prostate brachytherapy

Nucletron Prostate Solutions is the first complete program for prostate brachytherapy, integrating state-of-the-art Oncentra software and high-class brachytherapy equipment. Next to years of evidence confirming favorable cure rates, these advanced solutions shorten overall treatment times, while reducing risks of impotence and incontinence. Available for two treatment types - Oncentra(R) Seeds for permanent low dose rate (LDR) seeds implantation and Oncentra(R) Prostate for high dose rate (HDR) - it offers the best choice of treatment for many prostate cancer patients.

Breast brachytherapy: See what you treat, treat what you see

AccuBoost(TM) is the first technology to use HDR brachytherapy treatment of breast cancer in a non-invasive way, utilizing real-time mammography imaging to accurately target the radiation dose directly to the lumpectomy site. AccuBoost can be delivered either prior to or after the main external beam portion of a woman's breast irradiation treatment.

Pioneering developments in gynecological brachytherapy

Whether you use CT, MR or any other imaging modality, Nucletron can offer a suitable applicator for gynecological brachytherapy. The newest in our range of applicators are the Multichannel Vaginal Cylinder for asymmetrical and advanced vaginal and cervical tumors, and the Rotterdam Cervix Applicator, designed for fast and reproducible treatments. These two applicators give ultimate precision in gynecological brachytherapy.

Optimal speed and precision in treatment planning

Oncentra(R) 4.0 is the newest version of Nucletron's multi-modality treatment planning system for brachytherapy and external beam treatment. Oncentra v4.0 is the first ever platform to use GPU technology to increase plan accuracy and reduce planning times from hours to minutes, especially for VMAT calculations. New Oncentra Brachy features, such as applicator modeling, library plans and output manager, are specially developed to make brachytherapy treatment planning easier and faster.

Flexitron numbers talk

The Flexitron afterloader takes brachytherapy to a new level. It helps to shorten preparation time and reduces the chance of human errors with its straightforward Absolute Source Positioning. It sets a new safety benchmark, with features like the precise source drive. It's not just words, Flexitron's numbers talk and improve safety!

Visit Nucletron during ESTRO29 at booth 170 to find more information on the latest innovations in precision cancer treatment, and to receive a demo. Visit http://www.nucletron.com/estro29 for more information.

About Nucletron

Nucletron provides state of the art radiotherapy solutions for cancer treatment that meet the evolving needs of patients, their caregivers and healthcare professionals around the world. Nucletron has unmatched global leadership in brachytherapy, a very precise, highly effective and well-tolerated treatment option for healthcare providers, tailored to the needs of individual patients. We work with clinical teams to constantly improve and develop an innovative portfolio of integrated products, software and services that assures excellent patient outcomes. Headquartered in Veenendaal, The Netherlands, Nucletron employs more than 500 employees, with offices in 15 countries, and products available in more than 100 countries around the world. Please visit http://www.nucletron.com to learn more about our healthcare solutions.

http://www.nucletron.com


'/>"/>
SOURCE Nucletron
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy
2. Nucletron Announces 2008 Results
3. Nucletron Releases Comprehensive Film-and Volume-Based Planning System for Wide Variety of Brachy Solutions
4. Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market
5. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
6. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
7. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
8. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
9. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
10. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
11. Inverness Medical Innovations Announces Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):